BioNTech Showcases AI Progress at AI Day

Ticker: BNTX · Form: 6-K · Filed: Oct 1, 2024 · CIK: 1776985

Biontech Se 6-K Filing Summary
FieldDetail
CompanyBiontech Se (BNTX)
Form Type6-K
Filed DateOct 1, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: AI, subsidiary, presentation

TL;DR

BioNTech is going all-in on AI for drug discovery, presenting its latest AI tech via InstaDeep.

AI Summary

On October 1, 2024, BioNTech SE announced its participation in the AI Day presentation, highlighting its advancements in artificial intelligence through its subsidiary InstaDeep Ltd. The company is leveraging AI to drive innovation across its drug discovery and development processes.

Why It Matters

BioNTech's focus on AI integration signals a commitment to accelerating drug development timelines and potentially discovering novel therapies, which could impact future healthcare solutions.

Risk Assessment

Risk Level: low — This filing is an informational update about a presentation and does not contain material financial changes or new risks.

Key Players & Entities

  • BioNTech SE (company) — Registrant
  • InstaDeep Ltd. (company) — AI subsidiary
  • October 1, 2024 (date) — Date of announcement

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K is filed by BioNTech SE to report information regarding its participation in an AI Day presentation on October 1, 2024, showcasing advancements in artificial intelligence through its subsidiary InstaDeep Ltd.

Which subsidiary is involved in BioNTech's AI initiatives?

BioNTech's AI subsidiary, InstaDeep Ltd., is involved in the company's artificial intelligence initiatives.

When did BioNTech SE make this announcement?

BioNTech SE made this announcement on October 1, 2024.

What is the primary focus of BioNTech's AI efforts mentioned in the filing?

The filing indicates that BioNTech is leveraging AI to drive innovation across its drug discovery and development processes.

What is the company's principal executive office address?

BioNTech SE's principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany.

Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2024-10-01 08:12:03

Filing Documents

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On October 1, 2024, BioNTech SE (the "Company"), alongside its artificial intelligence ("AI") subsidiary InstaDeep Ltd., is presenting an overview of its AI approach during an edition of the Company's Innovation Series, AI Day. The press release and presentation are attached as Exhibits 99.1 and 99.2, respectively. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date October 1, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Highlights AI Capabilities and RD Use Cases at Inaugural AI Day 99.2 Presentation

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.